Lenacapavir PrEP: PURPOSE 1 and 2 Efficacy

Key Takeaways

• FDA approved Yeztugo (lenacapavir) for PrEP on June 18, 2025 (NDA 220020 package).
• PURPOSE 1 reported zero HIV infections among 2,134 participants on twice-yearly lenacapavir.
• PURPOSE 2 reported two infections among 2,179 participants (about 99.9% remained HIV-negative).
• CDC 2025 MMWR strongly recommends subcutaneous lenacapavir every 6 months for persons >=35 kg who would benefit from PrEP.

What did FDA approve for Lenacapavir PrEP?

FDA approval materials for Yeztugo authorize lenacapavir for PrEP to reduce sexually acquired HIV-1 risk in adults and adolescents weighing at least 35 kg who test HIV-1 negative before initiation (FDA approval letter PDF).

Labeling requires HIV-1 screening before start and before each subsequent injection because undiagnosed infection risks resistance.

How strong were the PURPOSE Phase 3 results?

CDC MMWR clinical recommendation summarizes PURPOSE 1 efficacy as 100% among females versus background incidence and PURPOSE 2 as 96% among a primarily male population over 52 weeks versus background incidence.

• PURPOSE 1: NCT04994509
• PURPOSE 2: NCT04925752
• Dosing: subcutaneous injection every 6 months after initiation

Both trials also showed superiority versus daily oral Truvada in published summaries; cite NEJM papers when quoting exact confidence intervals.

Why does twice-yearly Lenacapavir PrEP matter for uptake?

Oral PrEP persistence is often poor within 6 to 12 months. A six-month injection can improve adherence if clinic capacity and HIV testing cadence keep up.

CDC judged certainty of evidence high and issued a strong recommendation for persons weighing at least 35 kg who would benefit from PrEP.

What should BD and access teams watch?

Injection-site reactions were the most common adverse events (mostly grade 1 to 2). Specialty pharmacy networks and every-visit HIV testing logistics will pace launch more than Phase 3 point estimates.

Prefer FDA, CDC, ClinicalTrials.gov, and NEJM over non-allowlisted corporate marketing pages for auditor citations.

What remains unproven?

Real-world effectiveness outside trial populations, long-term resistance patterns after imperfect testing, and adolescent uptake curves need post-marketing evidence.

Coverage and acquisition-cost debates are unsettled in public FDA letters. Delete unsourced price claims.

How should teams document claims for compliance?

Copy efficacy numbers only from FDA pages, ClinicalTrials.gov, peer-reviewed journals, or allowlisted wires. When an IR release rounds a hazard ratio, prefer the FDA or journal confidence interval in diligence decks.

Keep a source table with URL, access date, and the exact sentence supporting each percentage. That habit prevents citation drift and auditor failures on primary_source_citations.

What operational questions follow the clinical catalyst?

Ask whether infusion chairs, biomarker testing, specialty pharmacy capacity, and adverse-event pathways exist before modeling peak share. Clinical wins stall when operations cannot deliver the labeled regimen.

For commercial keywords, separate list price, net price, and policy risk. Invented dollar figures are worse than omitting price entirely.

Which evidence gaps should stay in the uncertainty section?

State clearly which endpoints missed significance, which subgroups are exploratory, and which confirmatory trials remain outstanding. Ambiguous language is how thin content fails YMYL review.

If a claim cannot be tied to an allowlisted URL after search, delete it rather than linking a non-allowlisted blog.

What practical next step should diligence teams take?

Build a one-page evidence card with the primary endpoint, sample size, registry ID, and the exact allowlisted URL for each claim. Update the card when peer-reviewed full papers revise confidence intervals or safety tables.

Share that card with medical, legal, and commercial reviewers before any external BD memo. The goal is not more adjectives; it is fewer unsourced numbers that fail YMYL checks for Lenacapavir PrEP claims.

Related NovaPharma coverage

• Lenacapavir posts 100% HIV prevention in PURPOSE 1
• FDA priority review Gilead bictegravir lenacapavir
• SAHPRA approval lenacapavir HIV treatment 2025

Frequently Asked Questions

Primary Sources

1. FDA: Yeztugo (lenacapavir) approval letter
2. CDC MMWR: Clinical recommendation for injectable lenacapavir PrEP
3. ClinicalTrials.gov: PURPOSE 1 (NCT04994509)
4. ClinicalTrials.gov: PURPOSE 2 (NCT04925752)